证券代码：605116 证券简称：奥锐特 公告编号：2026-003 债券代码：111021 债券简称：奥锐转债 奥锐特药业股份有限公司 关于调整回购价格上限的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 奥锐特药业股份有限公司（以下简称"公司"）于 2026 年 1 月 12 日召开 的第三届董事会第十八次会议，审议通过了《关于调整回购股份价格上限的议 案》，公司拟将回购股份价格上限由不超过人民币 24.71 元/股调整为不超过人民 币 35.00 元/股，回购方案的其他内容不变。 本次调整回购价格上限事项无需提交公司股东会审议。 一、回购股份的基本情况 2025 年 1 月 21 日，公司召开第三届董事会第十二次会议，会议以 9 票同意、 0 票反对、0 票弃权审议通过了《关于以集中竞价交易方式回购公司股份方案的 议案》，同意公司以集中竞价交易方式回购公司股份，回购的股份全部用于转换 公司可转债。本次回购股份的资金总额为不低于人民币 6,000 万元（含），不高 于人民币 12,000 万元（含）， ...

Group 1 - The company, Aorite (605116.SH), announced a plan to adjust the maximum repurchase price of its shares from RMB 24.71 per share to RMB 35.00 per share [1]

Company Performance - The stock price of Aorite reached a historical high, increasing by 8.17% to 30.58 yuan, with a trading volume of 16.094 million shares and a transaction value of 470 million yuan, resulting in a turnover rate of 3.96% [2] - For the first three quarters, the company achieved an operating income of 1.237 billion yuan, representing a year-on-year growth of 13.67%, and a net profit of 354 million yuan, reflecting a year-on-year increase of 24.58% [2] - The basic earnings per share were reported at 0.8700 yuan, with a weighted average return on equity of 14.37% [2] Industry Overview - The pharmaceutical and biotechnology industry, to which Aorite belongs, experienced an overall increase of 1.62%, with 413 stocks rising and 11 stocks, including Weikang Pharmaceutical and Dian Diagnostics, hitting the daily limit [2] - Conversely, 76 stocks in the industry saw declines, with the largest drops recorded by Meihua Medical, Aipeng Medical, and *ST Changyao, with declines of 10.52%, 8.26%, and 8.05% respectively [2]

Core Viewpoint - The innovative drug sector has experienced a strong rally since the beginning of 2026, driven by favorable policies, improving fundamentals, and a recovering capital market [1][4]. Group 1: Market Performance - The innovative drug concept sector in A-shares has seen a continuous rise, with multiple stocks, including Hainan Haiyao and Beibete-U, reaching their daily limit [1]. - Since the start of 2026, the innovative drug sector has recorded four consecutive days of gains, with over ten stocks rising more than 20% in four trading days, and Beibete-U's stock price has increased by nearly 70% [1][2]. Group 2: Policy and Regulatory Environment - The National Medical Products Administration (NMPA) has optimized the review and approval process for urgently needed foreign drugs, encouraging simultaneous global research and application in China [3]. - In 2025, China approved 76 innovative drugs for market entry, surpassing the 48 approved in 2024, marking a historical high [3]. Group 3: Industry Drivers - The recent rally in the innovative drug sector is attributed to several factors, including the implementation of new national medical insurance drug lists, which support the sales and market promotion of innovative drugs [4]. - The sector is also benefiting from advancements in cutting-edge fields such as ADC and small nucleic acids, attracting capital interest [4]. Group 4: Investment Focus - The investment focus for 2026 is shifting towards overseas expansion and emerging technologies, with an emphasis on business development (BD) as a long-term trend for Chinese innovative drugs [5]. - Companies with rapid milestone achievements in BD are expected to attract more market attention and investment opportunities [5].

每经AI快讯，1月8日，创新药概念持续走强，海南海药、奥锐特、必贝特-U涨停，苑东生物、泰恩 康、汇宇制药-W、奥赛康、上海谊众等跟涨。 （文章来源：每日经济新闻） ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 累计转股情况：截至 2025 年 12 月 31 日，累计已有面值 9,000 元"奥 锐转债"转为公司 A 股普通股，累计转股股数为 353 股，占"奥锐转债"转股 前公司已发行普通股股份总额的 0.0001%。 未转股可转债情况：截至 2025 年 12 月 31 日，尚未转股的"奥锐转债" 面值为人民币 812,111,000 元，占"奥锐转债"发行总量的比例为 99.9989%。 证券代码：605116 证券简称：奥锐特 公告编号：2026-002 债券代码：111021 债券简称：奥锐转债 奥锐特药业股份有限公司 关于可转债转股结果暨股份变动公告 本季度转股情况："奥锐转债"自 2025 年 2 月 5 日起可转换为公司股票， 2025 年 10 月 1 日至 2025 年 12 月 31 日期间共有面值 1,000 元"奥锐转债"转 为公司 A 股普通股，转股后的股份数为 40 股。 一、可转债发行上市概况 （一）可转债发行情况 经中国证券监督管理委员 ...

1. Report Industry Investment Rating No relevant content provided. 2. Report's Core View The report presents the top ten convertible bonds in January 2026, including their credit ratings, closing prices at the end of December, conversion premium rates, and the trailing twelve - month price - to - earnings ratios (PE - TTM) of their underlying stocks. It also details the business profiles, financial performance, and key highlights of the companies corresponding to these convertible bonds [2][4][6]. 3. Summary by Company 3.1 Zhongte Convertible Bond - **Company Overview**: A globally leading specialized special - steel material manufacturer with an annual production capacity of about 20 million tons of special - steel materials. It has multiple production and raw - material bases, forming a coastal and riverside industrial chain layout [11]. - **Financial Performance**: In 2024, its operating income was 109.203 billion yuan (YoY - 4.22%), net profit attributable to the parent company was 5.126 billion yuan (YoY - 10.41%). In the first three quarters of 2025, operating income was 81.206 billion yuan (YoY - 2.75%), and net profit attributable to the parent company was 4.33 billion yuan (YoY + 12.88%) [11]. - **Company Highlights**: It is one of the world's most comprehensive special - steel enterprises in terms of variety and specification. It has a complete industrial chain, leading cost - control ability, and is seeking external expansion opportunities [12]. 3.2 Shanlu Convertible Bond - **Company Overview**: Focuses on road and bridge engineering construction and maintenance, and is expanding into other fields. It has a complete business and management system [29]. - **Financial Performance**: In 2024, its operating income was 71.348 billion yuan (YoY - 2.3%), net profit attributable to the parent company was 2.322 billion yuan (YoY + 1.47%). In the first three quarters of 2025, operating income was 41.354 billion yuan (YoY - 3.11%), and net profit attributable to the parent company was 1.41 billion yuan (YoY - 3.27%) [29]. - **Company Highlights**: It has the concept of China - specific valuation, potential for improvement in balance sheet and orders, benefits from regional infrastructure plans, and is exploring overseas markets [30]. 3.3 Hebang Convertible Bond - **Company Overview**: Has advantages in resource supply and has completed a basic layout in the chemical, agricultural, and photovoltaic fields, with four major business segments [44]. - **Financial Performance**: In 2024, its operating income was 8.547 billion yuan (YoY - 3.13%), net profit attributable to the parent company was 31 million yuan (YoY - 97.55%). In the first three quarters of 2025, operating income was 5.927 billion yuan (YoY - 13.02%), and net profit attributable to the parent company was 93 million yuan (YoY - 57.93%) [44]. - **Company Highlights**: Its phosphate mines and salt mines contribute profits, and its liquid methionine production is a major profit - contributor [45]. 3.4 Huayuan Convertible Bond - **Company Overview**: Focuses on building a complete vitamin D3 upstream - downstream industrial chain, with products in the vitamin and chemical - preparation fields [56]. - **Financial Performance**: In 2024, its operating income was 1.243 billion yuan (YoY + 13.58%), net profit attributable to the parent company was 309 million yuan (YoY + 60.76%). In the first three quarters of 2025, operating income was 936 million yuan (YoY - 0.2%), and net profit attributable to the parent company was 234 million yuan (YoY - 3.07%) [56]. - **Company Highlights**: It has leading products in the market, is expanding its product matrix, and has a strong layout in the pharmaceutical manufacturing field [57]. 3.5 Xingye Convertible Bond - **Company Overview**: One of the first joint - stock commercial banks in China, evolving into a modern financial service group with multiple financial licenses [70]. - **Financial Performance**: In 2024, its operating income was 212.226 billion yuan (YoY + 0.66%), net profit attributable to the parent company was 77.205 billion yuan (YoY + 0.12%). In the first three quarters of 2025, operating income was 161.234 billion yuan (YoY - 1.82%), and net profit attributable to the parent company was 63.083 billion yuan (YoY + 0.12%) [70]. - **Company Highlights**: It has stable asset quality and scale growth, with a large number of customers [71]. 3.6 Aima Convertible Bond - **Company Overview**: The leading enterprise in the electric two - wheeled vehicle industry, producing and selling electric bicycles, scooters, and motorcycles [80]. - **Financial Performance**: In 2024, its operating income was 21.606 billion yuan (YoY + 2.71%), net profit attributable to the parent company was 1.988 billion yuan (YoY + 5.68%). In the first three quarters of 2025, operating income was 21.093 billion yuan (YoY + 20.78%), and net profit attributable to the parent company was 1.907 billion yuan (YoY + 22.78%) [80]. - **Company Highlights**: It may benefit from government subsidies, new national standards, and has potential for improving gross margins [81]. 3.7 Chongyin Convertible Bond - **Company Overview**: The earliest local joint - stock commercial bank in the upper reaches of the Yangtze River and Southwest China, listed on the Hong Kong Stock Exchange and included in the "Leading Sheep" plan [90]. - **Financial Performance**: In 2024, its operating income was 13.679 billion yuan (YoY + 3.54%), net profit attributable to the parent company was 5.117 billion yuan (YoY + 3.8%). In the first three quarters of 2025, operating income was 11.74 billion yuan (YoY + 10.4%), and net profit attributable to the parent company was 4.879 billion yuan (YoY + 10.19%) [90]. - **Company Highlights**: It benefits from the regional economic development, has stable asset - scale growth, and actively adjusts its business strategies [91][94]. 3.8 Tianye Convertible Bond - **Company Overview**: The first industrial enterprise of the Xinjiang Production and Construction Corps, a leading enterprise in the chlor - alkali chemical industry with an integrated circular economy industrial chain [103]. - **Financial Performance**: In 2024, its operating income was 11.156 billion yuan (YoY - 2.7%), net profit attributable to the parent company was 68 million yuan (YoY + 108.83%). In the first three quarters of 2025, operating income was 7.97 billion yuan (YoY + 2.2%), and net profit attributable to the parent company was 7 million yuan (YoY - 28.79%) [103]. - **Company Highlights**: It has cost - advantage in caustic soda production and plans to increase dividend frequency and has coal - mine projects in progress [106]. 3.9 Aorui Convertible Bond - **Company Overview**: A company focusing on the R & D, production, and sales of complex APIs and preparations, leading in several technical fields [119]. - **Financial Performance**: In 2024, its operating income was 1.476 billion yuan (YoY + 16.89%), net profit attributable to the parent company was 355 million yuan (YoY + 22.59%). In the first three quarters of 2025, operating income was 1.237 billion yuan (YoY + 13.67%), and net profit attributable to the parent company was 354 million yuan (YoY + 24.58%) [119]. - **Company Highlights**: It is optimizing its distribution network, expanding its overseas market for preparations, and has high - quality customer resources [120]. 3.10 Yushui Convertible Bond - **Company Overview**: The largest water supply and drainage integrated enterprise in Chongqing, with a monopoly position in the local market [133]. - **Financial Performance**: In 2024, its operating income was 6.999 billion yuan (YoY - 3.52%), net profit attributable to the parent company was 785 million yuan (YoY - 27.88%). In the first three quarters of 2025, operating income was 5.568 billion yuan (YoY + 7.21%), and net profit attributable to the parent company was 779 million yuan (YoY + 7.1%) [133]. - **Company Highlights**: It has a high market share, is expanding its business regionally, and has achieved cost control through intelligent applications [134].

Company Summary - Aorite announced on January 4 that as of December 31, 2025, it has repurchased approximately 2.63 million shares through the Shanghai Stock Exchange, representing 0.65% of the company's total share capital [1] - The highest repurchase price was 22.59 CNY per share, while the lowest was 18.83 CNY per share, with a total expenditure of approximately 55.12 million CNY [1] Industry Insights - The article mentions significant predictions for 2026, including a potential 20% decline in the US stock market, the collapse of the AI bubble, and the disruptive impact of quantum computing on cryptocurrency [1] - Additionally, it highlights a forecasted surge in gold prices, potentially exceeding 10,000 USD [1]

格隆汇1月4日丨奥锐特(605116.SH)公布，截至2025年12月31日，公司通过上海证券交易所交易系统以 集中竞价交易方式已累计回购公司股份262.72万股，占公司目前总股本的比例为0.65%，回购成交的最 高价为22.59元/股，最低价为18.83元/股，支付的资金总额为人民币55,124,396.68元(不含交易费用)。 ...

| | | 奥锐特药业股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2025/1/22 | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 2025 年 1 1 月 | 月 | 21 | 日~2026 | 年 | 20 日 | | 预计回购金额 | 6,000万元~12,000万元 | | | | | | | 回购用途 | □减少注册资本 □用于员工持股计划或股权激励 | | | | | | | | √用于转换公司可转债 | | | | | | | | □为维护公司价值及股东权益 | | | | | | | 累计已回购股数 | 2,627,238股 | | | | | | | 累计已回购股数占总股本比例 | 0.65% | | | | | | | 累计已回购金额 | 55,124,396.68元 | | | | | | | 实际回购价格区 ...